An interventional study of Intrauterine Insemination and Clomiphene in Infertility, sponsored by Midwest Fertility Specialists. Completed at 2 sites in United States. Open to female participants aged 21 Years to 39 Years. Per ClinicalTrials.gov, last updated 2015-12-09.
Sponsored by Midwest Fertility Specialists · Not applicable and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing clomiphene in Infertility — 1 open to participants now, 4 under way, 1 of them phase 3. Clomiphene · Infertility.
Among the 33 studies testing clomiphene in Infertility, this one is the 29th largest by enrollment, is the only one that started in 2013, is one of 7 with no phase, and was the 20th registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 33 studies testing clomiphene in Infertility is open now, in 1 country. Recruiting first, the newest first:
PAEC General Hospital, Islamabad · Sites in Pakistan
Ages 18–38 · Women only · Healthy volunteers
By country, each count listing its studies:
Clomiphene: first FDA approval 1967 (CLOMID). What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 21 Years to 39 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 6 · Phase 4 19
First in 1991; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 154 across the 33 interventional studies. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 33 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Midwest Fertility Specialists as lead sponsor.
Midwest Fertility Specialists has 1 study filed under Infertility — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing clomiphene in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to assess the impact of the timing of intrauterine insemination (IUI) in relation to the natural surge of luteinizing hormone (LH), as detected by home ovulation predictor kits, on pregnancy rates per treatment cycle. The study will take place at the offices of Midwest Fertility Specialists and include patients who have been independently recommended by their primary physician to undergo ovulation induction with clomiphene citrate (CC) or letrozole and IUI as therapy for infertility.
Intrauterine insemination is a procedure that is performed in the physician's office. During the procedure the sperm from the male partner are placed directly into the female partner's uterus around the time of ovulation (release of oocyte or egg). Ovulation predictor kits, available over the counter at pharmacies, test for the presence of luteinizing hormone in the urine. When the test result is a positive, it means the hormone is present in the urine. This is a sign of ovulation. Physicians typically choose to perform intrauterine insemination either the day of a positive ovulation test or the day after a positive ovulation test. The purpose of this study is to determine if the day when intrauterine insemination is performed influences the chance of becoming pregnant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day the home ovulation predictor kit first turns positive.
Procedure: Intrauterine Insemination · Drug: Clomiphene · Drug: Letrozole
This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day after the home ovulation predictor kit first turns positive.
Procedure: Intrauterine Insemination · Drug: Clomiphene · Drug: Letrozole
Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.
Patient is to take clomiphene citrate during cycle days 3-7.
Also known as: clomid
Patient is to take letrozole during cycle days 3-7.
Number of Pregnancies Achieved Per Menstrual Cycle.
Time frame: Up to 3 months
Per Cycle Pregnancy Rate Based on Infertility Diagnosis
Time frame: Up to cycle day 35
Pregnancy Rate Per Female Partner Age
Pregnancy rate will be compared between patients \<35 and \>35 at time of study entry.
Time frame: Up to cycle day 35
Pregnancy Rate Per Semen Morphology Score
Comparison of pregnancy rate based on semen morphology of \<4% vs \>4% normal morphology scores.
Time frame: Up to cycle day 35
Pregnancy Rate Per Body Mass Index Category
Time frame: Up to cycle day 35
Patients recruited from two clinical offices from 1/2014 until 9/2015.
| Milestone | Insemination Day Of Positive OPK | Insemination Day After Positive OPK |
|---|---|---|
| Started | 7 | 6 |
| Completed | 7 | 4 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| pregnancies per cycle | Insemination Day Of Positive OPK | Insemination Day After Positive OPK |
|---|---|---|
| Number of Pregnancies Achieved Per Menstrual Cycle. | 0 | 0 |
| pregnancies per cycle | Insemination Day Of Positive OPK | Insemination Day After Positive OPK |
|---|---|---|
| Per Cycle Pregnancy Rate Based on Infertility Diagnosis | 0 | 0 |
Pregnancy rate will be compared between patients \<35 and \>35 at time of study entry.
| pregnancies per cycle | Insemination Day Of Positive OPK | Insemination Day After Positive OPK |
|---|---|---|
| Female age < 35 | 0 | 0 |
| Female age > 35 | 0 | 0 |
Comparison of pregnancy rate based on semen morphology of \<4% vs \>4% normal morphology scores.
| pregnancies per cycle | Insemination Day Of Positive OPK | Insemination Day After Positive OPK |
|---|---|---|
| Semen morphology < 4% | 0 | 0 |
| Semen morphology > 4% | 0 | 0 |
| pregnancies per cycle | Insemination Day Of Positive OPK | Insemination Day After Positive OPK |
|---|---|---|
| Body mass index normal | 0 | 0 |
| Body mass index overweight | 0 | 0 |
| Body mass index obese | 0 | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insemination Day Of Positive OPK | — | 0/7 (0%) | 0/7 (0%) |
| Insemination Day After Positive OPK | — | 0/6 (0%) | 0/6 (0%) |
| Age, Continuous(years) | Insemination Day Of Positive OPK | Insemination Day After Positive OPK | Total |
|---|---|---|---|
| Mean | 30.4 ± 5.9 | 29.6 ± 3.05 | 30.1 ± 4.8 |
| Sex: Female, Male(Participants) | Insemination Day Of Positive OPK | Insemination Day After Positive OPK | Total |
|---|---|---|---|
| Female | 7 | 6 | 13 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(participants) | Insemination Day Of Positive OPK | Insemination Day After Positive OPK | Total |
|---|---|---|---|
| United States | 7 | 6 | 13 |
| Body Mass Index(kg/m^2) | Insemination Day Of Positive OPK | Insemination Day After Positive OPK | Total |
|---|---|---|---|
| Mean | 30 ± 8.9 | 25 ± 4 | 27.9 ± 7.5 |
| Day 3 Follicle Stimulating Hormone(mIU/ml) | Insemination Day Of Positive OPK | Insemination Day After Positive OPK | Total |
|---|---|---|---|
| Mean | 7.6 ± 1.7 | 6.2 ± 1.9 | 6.9 ± 1.8 |
| Anti-mullerian Hormone(ng/ml) | Insemination Day Of Positive OPK | Insemination Day After Positive OPK | Total |
|---|---|---|---|
| Mean | 3.1 ± 2.2 | 5.8 ± 0 | 5.2 ± 2.3 |
| Sperm Concentration(million sperm/ml) | Insemination Day Of Positive OPK | Insemination Day After Positive OPK | Total |
|---|---|---|---|
| Mean | 32.6 ± 13.9 | 71.2 ± 39.2 | 39.4 ± 30.9 |
| Sperm morphology(Percent normal) | Insemination Day Of Positive OPK | Insemination Day After Positive OPK | Total |
|---|---|---|---|
| Mean | 5.6 ± 2.3 | 8.5 ± 2.4 | 6.2 ± 2.6 |
1 further baseline measures are reported on the registry.
The record gives a start of Oct 2013, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Clomiphene · Letrozole